F Lori
Overview
Explore the profile of F Lori including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
61
Citations
1875
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Toke E, Lorincz O, Csiszovszki Z, Somogyi E, Felfoldi G, Molnar L, et al.
Gene Ther
. 2014 Apr;
21(6):566-74.
PMID: 24694539
There is no clinically available cancer immunotherapy that exploits Langerhans cells (LCs), the epidermal precursors of dendritic cells (DCs) that are the natural agent of antigen delivery. We developed a...
2.
Gudmundsdotter L, Wahren B, Haller B, Boberg A, Edback U, Bernasconi D, et al.
Vaccine
. 2011 Feb;
29(33):5558-66.
PMID: 21300092
Immunotherapy in patients with HIV-1 infection aims to restore and broaden immunological competence, reduce viral load and thereby permit longer periods without combined antiretroviral treatment (cART). Twelve HIV-1-infected patients on...
3.
De Forni D, Stevens M, Lori F
Br J Pharmacol
. 2010 Sep;
161(4):830-43.
PMID: 20860662
Background And Purpose: Antiviral hyper-activation-limiting therapeutic agents (AV-HALTs) are a novel experimental drug class designed to both decrease viral replication and down-regulate excessive immune system activation for the treatment of...
4.
Lori F, Calarota S, Lisziewicz J
Curr Med Chem
. 2007 Aug;
14(18):1911-9.
PMID: 17691933
Highly active antiretroviral treatment (HAART), i.e. the combination of three or more drugs against human immunodeficiency virus type 1 (HIV-1), has greatly improved the clinical outcome of HIV-1-infected individuals. However,...
5.
Lori F, Foli A, Kelly L, Lisziewicz J
Curr Med Chem
. 2007 Feb;
14(2):233-41.
PMID: 17266582
In this review we discuss the features of a new class of antiretroviral combinations, namely "Virostatics". Virostatics are characterized by the combination of a drug directly inhibiting virus production (viro),...
6.
Lori F, Lisziewicz J
Antivir Ther
. 2005 Jul;
4 Suppl 3:101-8.
PMID: 16021881
Data from comparative trials involving more than 500 patients indicate that hydroxyurea is safe and augments suppression of HIV-1 replication when used in combination with didanosine or didanosine/stavudine as initial...
7.
Kelly L, Lisziewicz J, Lori F
Curr Pharm Des
. 2004 Dec;
10(32):4103-20.
PMID: 15579091
The combination of three or more antiretroviral drugs is referred to as highly active antiretroviral therapy (HAART) and constitutes the standard of care for HIV-1 patients in industrialized nations. Although...
8.
Lori F, Kelly L, Lisziewicz J
Curr Drug Targets Infect Disord
. 2003 May;
3(2):171-8.
PMID: 12769793
The induction of a Th-1 polarized immune response is believed to be advantageous when designing immunologic approaches for HIV therapy. DNA vaccines represent one of the best immunologic strategies capable...
9.
Foli A, Seminari E, Ravot E, Lisziewicz J, Lori F
J Biol Regul Homeost Agents
. 2002 May;
16(1):64-8.
PMID: 12003177
Highly active antiretroviral therapies (HAART) represent a major advance in the treatment of HIV infection. Although with HAART a substantial suppression of viral replication can be obtained, eradication of the...
10.
Lori F, Lisziewicz J
JAMA
. 2001 Dec;
286(23):2981-7.
PMID: 11743839
Antiretroviral drugs constitute a milestone in the treatment of human immunodeficiency virus (HIV) infection; however, emerging problems limit their long-term use, and an increasing number of patients interrupt the prescribed...